Why the study?
Patients with Fontan circulation are at high risk for atrial tachyarrhythmias, prompting this study to examine the efficacy and safety of amiodarone for managing these arrhythmias in adult Fontan patients.
What is the efficacy and safety of amiodarone in the management of atrial arrhythmias in adult Fontan patients?
What is the efficacy and safety of amiodarone in the management of atrial arrhythmias in adult Fontan patients?
Amiodarone has acceptable short-term efficacy for atrial arrhythmias in adult Fontan patients, but long-term use is limited by reduced efficacy and high rates of adverse effects, particularly thyrotoxicosis which exacerbates heart failure.
Answers are grounded in this paper and cite their sources.
Amiodarone warrants close monitoring for side effects in adult Fontan patients; leaves open need for RCTs on long-term strategies.
BACKGROUND: Patients with Fontan circulation are known to be at high risk for developing atrial tachyarrhythmias (AAs). Our objective was to examine the efficacy and safety of amiodarone in the management of ATs in adult Fontan patients. METHODS: Primary outcomes of this single-centre, retrospective study included freedom from AAs and incidence of adverse effects of amiodarone on Fontan patients. Heart failure (HF) events and composite outcomes of death from any cause, Fontan revision and heart transplantation were evaluated as secondary outcomes. Predictors of HF and discontinuing amiodarone were also evaluated. RESULTS: A total of 61 patients (mean age 31.6±11.3 years, 40.9% female), who were treated with amiodarone in between 1995 and 2018, were included. AAs free survival at 1, 3 and 5 years were 76.2%, 56.9% and 30.6%, respectively. During a median follow-up of 50.5 months, 34 (55.7%) patients developed side effects, and 20 (32.8%) patients discontinued amiodarone due to side effects. Thyroid dysfunction was the most common side effect (n=26, 76.5%), amiodarone-induced thyrotoxicosis (AIT) (n=16, 27.1%) being most common thyroid dysfunction. Young age (age <28.5 years) was associated with discontinuing amiodarone (HR 5.50, 95% CI 1.19 to 25.4, p=0.029). AIT significantly increased risk of HF (HR 4.82, 95% CI 1.71 to 13.6, p=0.003). CONCLUSIONS: Short-term efficacy of amiodarone in Fontan physiology is acceptable. However, long-term administration is associated with a reduction of efficacy and a significant prevalence of non-cardiac side effects. AIT is associated with exacerbation of HF. The judicious use of amiodarone administration should be considered in this population.
No takes yet. Share an insight, caveat, or question.
Kawada et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: